Merck announced on March 19, 2025, that Health Canada approved KEYTRUDA (pembrolizumab) in combination with carboplatin and paclitaxel, followed by Keytruda as a single agent. This approval is for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma.
The approval is based on data from the Phase 3 KEYNOTE-868 trial, also known as NRG-GY018, which demonstrated statistically significant improvements in progression-free survival. This expands Keytruda's indications in Canada, providing a new treatment option for patients.
This regulatory milestone reinforces Keytruda's broad utility across various cancer types and strengthens Merck's oncology portfolio in the Canadian market. It contributes to the continued growth of Merck's flagship product.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.